首页> 外文会议>International conference of molecular simulations and applied informatics technologies >Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptofic Bcl-2 family proteins: Characteristics of broad-spectrum protein binding and its effects on anti-tumor activity
【24h】

Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptofic Bcl-2 family proteins: Characteristics of broad-spectrum protein binding and its effects on anti-tumor activity

机译:抗凋亡Bcl-2家族蛋白广谱小分子抑制剂的设计,合成和活性评价:广谱蛋白结合的特征及其对抗肿瘤活性的影响

获取原文

摘要

On the basis of the comparison of the structure of the Bim BH3:Bcl-(x)(t) complex and that of the ABT-737:Bcl-(x)(L) complex,a series of class A compounds were designed.These compounds had the basic skeleton of ABT-737 and the h2 residues of Bim BH3.These residues had shown themselves to he relevant to Bim BH3's broad-spectrum binding properties in saturation mutagenesis assays.Unlike ABT-737,which is a selective inhibitor of anti-apoptotic members of the Bcl-2 protein family,the class A compounds showed broad-spectrum binding activity to target proteins similar to those of Bim BH3 peptide.Then class B compounds were synthesized by modifying the structure of the most effective dass A compound,A-4.Most of these class B compounds showed better binding affinity to the target proteins than the class A compounds bad.They also showed themselves more effective than ABT-737 at inhibiting growth in multiple tumor cell lines known to express Bcl-(x)(L).Bcl-2,and Mcl-1 proteins at high levels.Compounds B-11 and B-12 had the strongest anti-tumor activity of any compounds we produced.This study suggests that it is feasible to design small-molecule inhibitors based on the structure of Bim BH3,which shows broad-spectrum binding to Bcl-(x)(L) Bcl-2.and Mcl-1 proteins.Our results also suggest that the broad-spectrum properties of small-molecule inhibitors binding to target proteins play a critical role in inhibiting the growth of many tumor cells.Finally.our study provides a series of lead compounds that merit further research into anti-cancer therapeutics.
机译:基于BIM BH3:BCL-(X)(T)复合物的结构的比较和ABT-737:BCL-(X)(L)复合物的基础,设计了一系列类化合物。这些化合物具有ABT-737的基本骨架和BIM BH3的H2残基。这些残留物向自己表示与BIM BH3在饱和诱变诱变测定中的广谱结合性质相关.Unlike ABT-737,这是一种选择性抑制剂Bcl-2蛋白家族的抗凋亡成员,A类化合物向靶蛋白显示出与BIM BH3肽相似的靶蛋白的广谱结合活性。通过改变最有效的DAS的结构来合成B类化合物的化合物,这些B类化合物的A-40比例对靶蛋白的亲和力更好地表现出比疾病的阶级更好的亲和力。他们也表明自己比ABT-737更有效地抑制表达BCL-的多种肿瘤细胞系中的生长( x)(l).bcl-2,和high级别的mcl-1蛋白磅B-11和B-12具有我们所产生的任何化合物的最强的抗肿瘤活性。本研究表明,基于BIM BH3的结构设计小分子抑制剂是可行的,其显示与BCL的广谱结合 - (x)(l)bcl-2.和mcl-1蛋白。您的结果还表明,与靶蛋白结合的小分子抑制剂的广谱特性在抑制许多肿瘤细胞的生长方面发挥着关键作用。最后。我们的研究提供了一系列铅化合物,其优异地研究抗癌治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号